Kingsley is a Senior Partner at tranScrip. He is an accomplished, versatile medical professional with over 23 years of experience in clinical medicine and the bio-pharmaceutical industry (CROs, biotech and pharma companies); adept and ready to oversee the direction, planning, execution, and interpretation of clinical trials and data collection. Demonstrated expertise in pharmaceutical medicine with success completing over 300 studies in all therapeutic areas with core concentrations in oncology, cardiometabolism, immunology, neurosciences and rare diseases.
Kingsley was most recently Medical Director at Avadel Pharmaceuticals where he was the medical and safety lead on a global development program in narcolepsy. He was a significant contributor to various other development programs including Osimertinib (Tagrisso - AstraZeneca), ex-US lead of the BEACON Study (Reata Pharmaceuticals), etc.
Kingsley graduated from the College of Medicine, University of Port Harcourt, Nigeria (Pharmacology; Medicine & Surgery). He undertook residency training in internal medicine and nephrology and is a fellow of both the International Society for Peritoneal Dialysis (ISPD) and the International Society of Nephrology (ISN). Postgraduate education includes a postgraduate diploma in health research (Leeds, UK) and MSc in pharmaceutical medicine (Surrey, UK). He is a Fellow of the Faculty of Pharmaceutical Medicine (FFPM). He had his business/management education at Warwick Business School (MBA) and entrepreneurial education at Cambridge Judge Business School.